The National Center for Advancing Translational Sciences awarded a purchase order to A1 Biochem Labs LLC on September 11, 2026, with a ceiling value of $69,352.00 for synthesis of five custom chemical compounds and intermediates supporting Ewing sarcoma research. Performance occurs in Rockville, Maryland, with an ultimate completion date of February 26, 2027. The contractor shall synthesize and deliver 5 grams each of five target compounds (ABCL-0482, A1-133143, A1-133142, ABCL-0485, and A1-133147) under non-GMP conditions with minimum 95% purity, accompanied by Certificates of Analysis for each compound. Deliverables include the synthesized compounds, biweekly written progress updates, and final shipment notification. Performance begins upon purchase order receipt and continues for up to 12 weeks. This firm-fixed-price acquisition was conducted under FAR 12.603 for commercial items with full and open competition, originating from a solicitation posted August 7, 2026, with responses due August 24, 2026.